Atlas Trials

First-in-human Safety and Immunogenicity Study of SCB-1019 and SCB-1019T in Healthy Adults

Clinical trial NCT06194318 · COMPLETED

Trial details

NCT number
NCT06194318
Sponsor
Clover Biopharmaceuticals AUS Pty
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Respiratory Syncytial Virus Vaccination
Start date
2023-12-13
Primary completion
2025-02-26
Enrollment
160

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.